1102presults of the Extension Trial of Optim, a Multicenter, Randomized Phase 3 Trial of Talimogene Laherparepvec (t-vec) Vs Gm-csf for Unresected Stage Iiib-iv Melanoma.

@article{Nemunaitis20141102presultsOT,
  title={1102presults of the Extension Trial of Optim, a Multicenter, Randomized Phase 3 Trial of Talimogene Laherparepvec (t-vec) Vs Gm-csf for Unresected Stage Iiib-iv Melanoma.},
  author={John Nemunaitis and Robert H I Andtbacka and Merrick I. Ross and Thomas T. Amatruda and Jason A Chesney and Frances Collichio and K J Harrington and Neil M. Steven and Sameul Fourie and Lydia M. Dreosti and Ai Li and Kate Liu and Mark Shilkrut and Robert S. Coffin and Howard L. Kaufman},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2014},
  volume={25 suppl_4},
  pages={iv382}
}

From This Paper

Topics from this paper.
3 Citations
0 References
Similar Papers

Similar Papers

Loading similar papers…